Posted by Michael Wonder on 12 Jul 2016
FDA approves Shire’s Xiidra (lifitegrast 5% ophthalmic solution) – the only treatment indicated for the signs and symptoms of dry eye disease
11 July 2016 - Xiidra is the first prescription eye drop FDA-approved to treat both the signs and symptoms of dry eye disease.
Shire announces that the U.S. FDA has approved Xiidra (lifitegrast 5% ophthalmic solution), a twice-daily eye drop solution indicated for the treatment of the signs and symptoms of dry eye disease in adult patients. Xiidra is the only prescription eye drop indicated for the treatment of both signs and symptoms of this condition.
Shire expects to launch Xiidra in the United States in the third quarter of 2016.
